Xgrast 300 MCG Injection 1 ML is primarily used to manage the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies who are undergoing myelosuppressive anti-cancer therapies. This medicine is a part of the granulocyte colony-stimulating factor (G-CSF) class of medications.
In addition to this primary use, this injection also helps reduce the time to neutrophil recovery and the duration of fever in patients with acute myeloid leukaemia (AML). It also aids in mobilising autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. It increases survival in patients who have been exposed to myelosuppressive doses of radiation.
Before using this medicine, inform your doctor about any pre-existing conditions or ongoing medications. If you notice any side effects while taking this medicine, notify your doctor immediately. For optimal results, Continue administering the injection for the duration prescribed by your doctor.